Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 9,159 matching trials from the live ClinicalTrials.gov search.
Conditions
Spinal Fractures, Fractures, Compression, Back Injuries
Interventions
Vertebral augmentation
Device
Lead sponsor
Benvenue Medical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Encinitas, California • Mountain View, California • Sacramento, California + 12 more
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Conditions
Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Interventions
Itolizumab, EQ001 Placebo
Biological · Drug
Lead sponsor
Equillium
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Completed Not applicable Interventional Results available

Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain

NCT03381248
Conditions
Osteoarthritis of the Knee
Interventions
Cooled Radiofrequency, Hyaluronic Acid Injection, Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Device · Other
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Coeur d'Alene, Idaho • New Orleans, Louisiana • Rochester, Minnesota + 7 more
Conditions
Lung Cancer
Interventions
Blood collection
Procedure
Lead sponsor
Nucleix Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
6,182 participants
Timeline
2021 – 2025
U.S. locations
27
States / cities
Encinitas, California • Lakewood, Colorado • West Haven, Connecticut + 22 more
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Conditions
Respiration
Interventions
Optical breath-hold control system (OBC)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Solid Tumor Malignancy
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
44
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
additional educational material, Standard of care
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Primary Hyperoxaluria Type 1, End Stage Renal Disease
Interventions
DCR-PHXC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Conditions
Contraception
Interventions
ESS505 (BAY1454033)
Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 44 Years · Female only
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
17
States / cities
Aurora, Colorado • Denver, Colorado • Wellington, Florida + 14 more
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
Conditions
Immunoglobulin G4 Related Disease
Interventions
Rilzabrutinib, Placebo, Glucocorticoid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
21
States / cities
Fontana, California • Sacramento, California • San Jose, California + 18 more
Conditions
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunscreen, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
208
States / cities
Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more
Conditions
Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 84 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 6 more
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Scottsdale, Arizona • Brandon, Florida • Miami, Florida + 23 more
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more
Completed No phase listed Observational Accepts healthy volunteers

Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

NCT00943527
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed
Interventions
ID-LV305
Biological
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Completed Phase 3 Interventional Results available

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

NCT02721069
Conditions
Acute Repetitive Seizures, Breakthrough Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Rochester, Minnesota • St Louis, Missouri + 2 more
Conditions
Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, fluorouracil, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota